For NMPA registration of EEG machines in China, the specific requirements regarding the number of clinical trials can vary based on several factors, including the device classification, intended use, and risk level. Here are some general considerations:

1. Device Classification

• Class I Devices: Typically do not require clinical trials if they can demonstrate equivalence to a predicate device.

• Class II Devices: May require clinical trials, especially if the device has new or significant changes compared to existing devices.

• Class III Devices: Generally require clinical trials to demonstrate safety and efficacy, as they pose higher risks to patients.

2. Intended Use and Novelty

• Novel Devices: Devices with new technology or intended for new indications may require more extensive clinical evidence, including multiple clinical trials.

• Existing Devices: Devices that can demonstrate substantial equivalence to predicate devices with existing clinical data may require fewer trials.

3. NMPA Guidance and Requirements

• Guidance Documents: Refer to specific NMPA guidance documents or regulations applicable to EEG machines to determine exact requirements for clinical trials.

• Sensitivity and Specificity: For diagnostic devices like EEG machines, sensitivity and specificity studies are crucial. These studies may be conducted as part of clinical trials or separately to establish diagnostic accuracy.

4. Other Considerations

• Study Design: The study design (e.g., randomized controlled trial, observational study) should be appropriate to gather robust clinical data supporting the device's safety and efficacy claims.

• Statistical Power: Ensure that the sample size and design provide adequate statistical power to detect clinically meaningful differences and establish the device's performance.

5. Expert Consultation and Regulatory Support

• Consult Regulatory Experts: Work with consultants or regulatory affairs specialists familiar with Chinese medical device regulations to interpret specific requirements and plan accordingly.

• Pre-Submission Meetings: Consider requesting a pre-submission meeting with NMPA to discuss clinical trial requirements and obtain clarity on expectations.

Contact Us：

Whatsapp or Wechat：+86 15816864648；email address：hito.lin@grzan.cn